Lipid Nanocarriers with Antifungal Activity Prepared by High Pressure Homogenization

ALIN BORS, GABRIELA NICULAE, RALUCA STAN*, AURELIA MEGHEA

Politehnica University Bucharest, Faculty of Applied Chemistry and Materials Science, 1 Polizu Str., 011060, Bucharest, Romania

Nanostructured lipid carriers (NLC) are promising nanoparticulate delivery systems produced from blends of liquid and solid lipids. In the present paper, the influence of different synthesis parameters (e.g. pressure, homogenization cycle, surfactant and drug concentrations, lipid blends etc.) on the main particles diameters of Nystatin-loaded NLC prepared by high pressure homogenization method have been monitored by dynamic light scattering technique. NLC formulations were prepared using two different lipid mixtures (Emulgade, Glycerol monostearate and Savory oil) and using two surfactants systems as stabilizing agents. Dynamic light scattering measurements performed on NLC showed that the oil nanocompartments incorporated into NLC solid matrix provide a good distribution of the antifungal agent inside the nanocarrier system. The percentage of encapsulated Nystatin is influenced by the concentration of Savory oil and lipid blend. From the results obtained, the prepared lipid nanocarriers showed an increase of Nystatin entrapment for 1% loading in comparison with 0.5% loading. Chemiluminescence assay proved that the protective activity against oxygen free radicals has been increased by incorporation of Savory oil into lipid nanocarriers.

Keywords: lipid nanocarriers, nystatin, high pressure homogenization

Nanostructured lipid carriers (NLC) are new colloidal systems having submicron particles with spherical shape and average diameters ranging from 50 to 500 nm [1, 2].

NLC are solid at body temperature being made by a blend of solid and liquid lipids dispersed in an aqueous medium and stabilized by surfactants [3, 4]. The lipid core is able to encapsulate lipophilic drugs [5-8], particularly between the imperfections of the crystal lattice [9], offering protection for chemical unstable compounds [10, 11]. As drug delivery systems, they present many more advantages such as physical stability, biodegradability, biocompatibility and controlled drug release [12-14]. Because of their versatility, NLC are very promising systems in many applications (e.g. parenteral, oral and dermal formulations) [15].

Natural products are valuable sources of bioactive compounds that can be used for multiple therapeutic purposes. The disadvantage of natural products is their low bioavailability and various studies were performed in order to valorize and to increase their efficacy by tailoring these complex systems at nanometer size [16-18]. Vegetable oils and selective plant extracts used for the development of lipid nanoparticles demonstrated an enhancement of their bioactive properties [19].

Nystatin (Nys) is also a natural product of *Streptomyces noursei* that has been used as a topical fungicidal drug since 1950s. It is active against *Candida, Cryptococcus, Histoplasma, Blastomyces* and *Aspergillus spp* [20]. Because of its toxicity, the use of Nys is limited to topical application and several studies were done in order to reduce its toxicity while preserving the antifungal activity by incorporation into liposomes [21] and solid lipid nanoparticles [22].

The aim of the present study is to incorporate Nystatin into NLC prepared based on Savory oil in order to develop formulations with enhanced antifungal properties and reduced toxicity. In this respect, the synthesis parameters of Nys-loaded NLC by high pressure homogenization

method have been systemically controlled and optimized in order to obtain a suitable carrier system.

Experimental part

Materials and methods

Polyoxyethylenesorbitan monolaurate (Tween 20) and Polyoxyethylenesorbitan monoleate (Tween 80) were purchased from Merck (Germany). Poloxamer 407 (block copolymer of polyethylene and polypropylene glycol) was supplied by (Germany) and Soybean lecithin by (Germany). Emulgade (a mixture of Glyceryl Stearate, Ceteareth-20, Ceteareth-12, Cetearyl Alcohol, Cetyl Palmitate) and Glycerol monostearate (GM) were supplied by (Germany). Savory oil (SO) was a gift from (Romania). Nystatin was supplied also by (Romania) and 3-amino-phthalhydrazide (Luminol) was purchased from Sigma Aldrich Chemie GmbH.

Synthesis of lipid nanocarriers

Nanostructured lipid carriers (NLCs) were prepared using a combination of high shear and high pressure homogenization techniques. The lipid phase, in a concentration of 10 or 12% and consisting in Em, GS and savory oil in various ratios (4.5:4.5:1, 4:4:2, 3.5:3.5:3 w/w), was heated under stirring at 85°C. Nys was added into the lipid phase and stirred until a clear molten solution was formed. The aqueous phase containing 2.5 or 3% surfactants mixture, Tween/Lecitihin/Block copolymer in a ratio of 8:1:1, was also heated under stirring at the same temperature (85 °C). The lipid phase was gradually added into the aqueous phase and stirred for 0.5 h at 85 °C. The formed pre-emulsion was mixed for 1 min at 12000 rpm using a high-shear homogenizer (PRO250 type; 0~28.000 rpm; power of 300 W, Germany) and it was further subject to a high-pressure homogenization (APV 2000 Lab Homogenizer, Germany) at various pressures (600 and 800 bar) and number of cycles (6 and 9). The nanoemulsions were cooled at room temperature for obtaining solid lipid

^{*} email: rl_stan2000@yahoo.com; Tel.: +40213154193

nanocarriers. In order to remove the excess of water, the dispersions were frozen at - 25 °C overnight and they were lyophilized for 72 h at -55 °C, using an Alpha 1-2 LD Freeze Drying System (Germany).

Characterization of nanostructured lipid carriers Particles size measurements

The mean particles diameter and size distribution of NLC were analyzed by dynamic light scattering (DLS) using a Zetasizer Nano ZS (United Kingdom). The mean particle size ($Z_{\rm av}$) and the polydispersity index (PdI) of the aqueous lipid nanodispersions were measured at a scattering angle of 90° and at a temperature of 25°C. Before measurements, the dispersions were diluted with deionized water to an adequate scattering intensity. The particle size data were evaluated using intensity distribution. The average diameters (based on Stokes-Einstein equation) and the polydispersity index were given as average of three individual measurements.

Zeta potential analysis

The Zeta potential (ZP) was determined by measuring the electrophoretic mobility of the nanoparticles in an electric field, by using the Helmholtz-Smoluchowsky equation. Prior to the measurements, which were performed with the appropriate accessory of Zetasizer Nano ZS (U.K.), the nanostructured lipid carriers in dispersion were diluted with a sodium chloride solution (0.9%, w/v), to adjust the conductivity to 50 μS/cm. All measurements were performed at 25°C in triplicate and the mean value was reported.

Determination of Nystatin entrapment efficiency

For the investigation of the entrapment efficiency of Nys into the lipid core, the concentration of Nys in the lyophylized samples was evaluated using UV-VIS spectroscopy. The entrapment efficiency of Nys into NLC has been calculated according to the relation:

$$EE\% = \frac{C_{Nys} - C_{unloadedNys}}{C_{Nys}} \tag{1}$$

where, $C_{\scriptscriptstyle Nys}$ is the concentration of Nys, which was initially added into lipid nanocarriers and $C_{\scriptscriptstyle unloadedNys}$ is the UV-Vis analyzed concentration of free Nys.

Evaluation of the antioxidant activity (AA %)

The *in vitro* antioxidant activity of loaded-NLCs and free-NLCs has been determined by chemiluminescence method (CL) using a Chemiluminometer Turner Design TD 20/20, USA. Luminol has been used as light amplifying substance. $\rm H_2O_2$ in Tris-HCl buffer solution ($p\rm H$ 8.6) has been used as generator system for free radicals. The samples were subject to ultrasonication for 3 min before the antioxidant activity determination. The antioxidant activity (percentage

of free radical scavenging) of unloaded- and loaded-NLC was compared with the same concentration of free (unloaded) Nys and savory oil individual solutions and was calculated by using the relation [23]:

$$\%AA = \frac{I_0 - I_s}{I_0} \times 100 \tag{2}$$

where I_0 is the maximum CL for standard at t = 5 s; I_s is the maximum CL at t = 5 s, for sample.

Results and discussions

Optimization of process parameters for synthesis of lipid nanocarriers

The synthesis of nanostructured systems obtained by combining solid lipids (Em and GM) with liquid lipids (SO), which was stabilized with a surfactants mixture, has firstly involved an optimization stage of the homogenization parameters. In this context, keeping constant the concentration of the lipid mixture (10% of the total weight), a number of lipid carriers has been synthesized by varying the pressure and the number of the homogenization cycles. Table 1 gives an overview on the produced formulations. The size and zeta potential values of all synthesized unloaded lipid nanocarriers are presented in figure 1 and 2, respectively.

By analyzing the results obtained from DLS, lipid nanocarriers with diameters smaller than 200 nm and variable polydispersity index can be observed. The increased pressure applied in the synthesis procedure has led to a decrease in the average diameters of the resulted nanoparticles. The same effect, with few exceptions, was observed by increasing the number of cycles from 6 to 9.

The two concentrations of surfactants used, 2.5 and 3%, did not determine notable differences between the sizes of NLC. Instead, as it was expected, the type of surfactant influences the size of NLC, thus the NLCs prepared with Tween 80 present smaller particle sizes than those prepared with Tween 20. Regarding the ZP, in general, the values were around -20 mV, which reflects a poor stability of the




Fig. 1. Particle size (Z_{av}) and polidispersity index (Pdl) of unloaded

surfactant Tween 80 NLC 9 NLC 10 NLC 11 NLC 12 NLC 13 NLC 14 NLC 15 NL Surfactants concentration 2.5% 3% HPH Pressure 600 bar 800 bar 600 bar 800 bar	Main	Tween 20	NLC 1	NLC 2	NLC 3	NLC 4	NLC 5	NLC 6	NLC 7	NLC 8
concentration 2.5% 3%	surfactant	Tween 80	NLC 9	NLC 10	NLC 11	NLC 12	NLC 13	NLC 14	NLC 15	NLC 16
HPH Pressure 600 bar 800 bar 600 bar 800 bar			2.5%				3%			
	HPH	Pressure	600 bar		800 bar		600 bar		800 bar	
parameters HPH cycle 6 9 6 9 6 9 6	parameters	HPH cycle	6	9	6	9	6	9	6	9

Table 1PROCESS AND SYNTHESIS
PARAMETERS OF THE DEVELOPED
UNLOADED-NLC

All samples were prepared with 10% (w/w) lipid blend, in a ratio of Em:GM:SO = 4.5:4.5:1, and with the surfactant mixture in a ratio of Tween/Lecithin/Block copolymer = 8:1:1.





Fig. 2. Zeta potentials (ZP) of unloaded NLC

unloaded NLC. Figures 3 and 4 show the particle size distribution and zeta potential of some selected lipid nanoparticles.

By correlating all the processes and synthesis parameters, the best results, in terms of size, were obtained by applying a pressure of 800 bar and 6 cycles of homogenization (e.g. 93.5 nm and PdI of 0.214 for NLC 7 prepared with 3% surfactants mixture and 88.7 nm and PdI of 0.189 for NLC 11 prepared with 2.5% surfactants mixture).

Particles size analysis of Nystatin loaded lipid nanocarriers prepared with various concentrations of lipid blends

Starting from the optimized systems, which were synthetized with Tween 80/Lecitihin/Block copolymer in a concentration of 2.5% and using the HPH parameters of 800 bar and 6 cycles, some NLCs were developed for an effective encapsulation of Nys. In this sense, the Nys concentration, the lipid blend composition and Savory oil concentration were varied in order to obtain efficient nanocarriers with appropriate size distribution and physical stability. The characteristics of the developed Nys-loaded lipid nanocarriers are shown in figures 5 and 6, while figures 7 and 8 exemplify the particle size distribution and zeta potential of 0.5% Nys-loaded lipid nanoparticles based on 12% lipids, of which 3% are SO.







Fig. 3. Size distribution of lipid nanocarriers prepared in various HPH conditions (selected samples)






Fig. 4. Zeta potential of lipid nanocarriers prepared in various HPH conditions (selected samples)

Even the average hydrodynamic diameters of the lipid nanocarriers prepared with 10% lipid blend (in a weight ratio of solid lipids to savory oil of 9:1, 8:2 and 7:3) were lower than those prepared with 12%, an optimum ratio between Z and PdI was obtained for the last composition (e.g. $121.4\,\mathrm{nm}$ and PdI of 0.237 for NLC prepared with 12% lipid blend versus 119.1 nm and 0.345 for NLC prepared with 10%).

The results obtained by varying the savory oil content (1%, 2% and 3% of the total weight of the nanodispersion) indicated the formation of nanostructures with main diameters ranging between 112 and 168 nm (for a lipid blend of 10%) and between 116 and 196 nm (for a lipid blend of 12%). The influence of savory oil concentration on Z_{av} has revealed a constant decrease of the average size as the oil content has been increased (e.g. 149.1 nm for NLC prepared with 10% SO and loaded with 0.5% Nys *versus* 121.4 nm for NLC prepared with 30% SO). These results may be related to lower viscosity samples and therefore a better homogenization can be ensured.

Regarding the effect of Nys encapsulation on Z_{av} and PdI, no significant changes have been observed by increasing the concentration of the antifungal compound from 0.5 to 1% (fig. 5). These results underline the efficiency of Em, GM and SO in formation of a lipid core with an appropriate network for the encapsulation of various active concentrations.

Physical stability of the aqueous dispersion of lipid nanocarriers

The physical stability of the lipid nanocarriers has been evaluated by zeta potential measurements. The zeta potential values obtained for several Nys-loaded lipid nanocarriers meet the required conditions for a good stability in time under the investigated condition. Interesting is the antifungal agent influence on physical stability of the synthesized lipid nanodispersions. The free nanocarriers show low physical stability, with zeta potential values higher in absolute value than -17 mV, while the Nys incorporation leads in almost all prepared nanocarriers to more electronegative zeta potentials, e.g. from -21mV to -30 mV.




Fig. 5. Particle size (Z_{av}) and polidispersity index (PdI) of Nystatin-loaded lipid nanocarriers and of unloaded-lipid nanocarriers




Fig. 6. Zeta potential (ZP) of Nystatin-loaded lipid nanocarriers and of unloaded-lipid nanocarriers




Fig. 7. Size distribution of NLC 28 loaded with 0.5% Nystatin




Fig. 8. Zeta potential distribution of NLC 28 loaded with 0.5% Nystatin

The zeta potential distribution for selected lipid nanocarriers loaded with antifungal agent is exemplified in figure 6. The most stable nanocarriers have been prepared with 12% lipid blend and loaded with 0.75% Nys, with a mean potential value of - 25.4, -28.4 and -30.4 mV, respectively. In general physical stability increased with increasing the amount of savory oil from 10 to 30%. These results confirm the distribution of the antifungal agent in




Fig. 9. Entrapment efficiency (%) of Nystatin loaded into lipid nanocarriers

the outer shell of the lipid core, which led to a change in surface charge.

Determination of Nystatin encapsulation

In order to assess the solubilization capacity of the antifungal agent in the lipid nanocarriers, the entrapment efficiency (EE%) was determined (fig. 9). Contrary to expectations, increasing the loading of the antifungal agent resulted in an increase of the encapsulation efficiency. For instance, a load of 0.5% Nys has led to an entrapment between 40 and 82.6%, while the encapsulation of 1% active increased significantly the EE% up to 95.5%. Regarding the influence of savory oil on the encapsulation efficiency no major changes have been reported depending on the oil content.




Fig. 10. Antioxidant activity (%) of Nystatin-loaded lipid nanocarriers based on Savory oil

Antioxidant activity of NLC

The antioxidant activity (%) of NLC, which is mainly ensured by SO, is shown in figure 10. AA values of different concentrations of SO (1, 2, 3%) encountered in NLC were compared with those of unloaded (free) SO. It can be observed that increasing the oil concentration from 1 to 3%, the AA is improved for both unloaded-lipid nanocarriers and individual oil solution systems. This behaviour is also observed for a low concentration of Nys (0.5%) loaded into NLC prepared with 10% or 12% lipids, while for higher concentration of Nys (0.75% and 1%) the AA of NLC drops with increasing the oil content.

Conclusions

The antifungal lipid nanocarriers with main average diameters ranging between 114 and 200 nm are obtained by using high pressure homogenization method. The zeta potential values of the nanodispersions (< -30 mV) revealed a moderate stability in time of the NLC. The presence of savory oil in low concentration has led to a decrease of the particle size, while the physical stability was better in case of NLC prepared with 12% lipid blend and loaded with 0.75% Nystatin. The prepared lipid nanocarriers offer an increased encapsulation of Nys for an initial 1% loading in comparison with 0.5% loading (e.g. entrapment efficiency reached 90% for 1% Nys and 82% for 0.5%, respectively). The antioxidant activity of Savory oil is increasing by incorporation into lipid nanocarriers, reaching up to 90% of oxygen free radicals scavenged.

The results obtained in the present study demonstrated that lipid nanocarriers based on emulgade, glyceryl monostearate and savory oil could be successfully used for the encapsulation of Nystatin in order to obtain antifungal formulations.

Acknowledgments: The work has been funded by the Sectoral Operational Programme Human Resources Development 2007-2013 of the Romanian Ministry of Labour, Family and Social Protection through the Financial Agreements POSDRU/107/1.5/S/76903.

References

- 1. PURI, D., BHANDARI, A., SHARMA, P., CHOUDHARY, D., J. Global Pharma. Tech., 2, 2010, p. 1.
- 2. MÜLLER, R.H., PETERSEN, R.D., HOMMOSS, A., PARDEIKE, J., Adv. Drug Delivery Rev., **59**, 2007, p. 522.

- 3. PARDEIKE, J., HOMMOSS, A., MULLER, R.H., Int. J. Pharmaceut., **366**, 2009, p. 170.
- 4. JOSHI, M.D., MÜLLER, R.H., Eur. J. Pharm. Biopharm., **71**, 2009, p. 161.
- 5. LACATUSU, I., BADEA, N., MURARIU, A., BOJIN, D., MEGHEA, A., Mol. Cryst. Liq. Cryst., **523**, 2010, p. 247.
- 6. LACATUSU, I., BADEA, N., MURARIU, A., MEGHEA, A., Nanoscale. Res. Lett., 2011, **6**, p. 73.
- 7. NICULAE, G., LACATUSU, I., BADEA, N., MEGHEA, A., Nanotechnology, **23**, 2012, p. 315704.
- 8. GUPTA, M., VYAS, S.P., Chem. Phys. Lipids., 165, 2012, p. 454.
- 9. XIA, Q., SAUPE, A., MULLER, R.H., SOUTO, E.B., Int. J. Cosmet. Sci., **29**, 2007, p. 473.
- 10. MITRI, K., SHEGOKAR, R., GOHLA, S., ANSELMI, C., MÜLLER, R.H., Int. J. Pharmaceut., **414**, 2011, p. 267.
- 11. JENNING, V., GOHLA, S.H., J. Microencapsul., 18, 2001, p. 149.
- 12. NICULAE, G., BADEA, N., MEGHEA, A., OPREA, O., LACATUSU, I., Photochem. Photobiol., **89**, 2013, p. 1085.
- 13. SCHÄFER-KORTING, M., MEHNERT, W., KORTING, H.C., Adv. Drug. Deliv. Rev., **59**, 2007, p. 427.
- 14. RAZA, K., SINGH, B., SINGAL, P., WADHWA, S., KATARE, O.P., Colloid. Surface. B, 105, 2013, p. 67.
- 15. GASCO, M.R., Adv. Drug. Deliv. Rev., 59, 2007, p. 377.
- 16. LACATUSU, I., BADEA, N., BOJIN, D., IOSUB, S., MEGHEA, A., J Sol-Gel Sci Techn, **51**, 2009, p. 84.
- 17. LACATUSU, I., BADEA, N., NITA, R., GIURGINCA, M., BOJIN, D., IOSUB, I., MEGHEA, A., J. Phys. Org. Chem., **22**, 2009, p. 1015.
- 18. BARBINTA-PATRASCU, M.E., BUNGHEZ, I.R., IORDACHE, S.M., BADEA, N., FIERASCU, R.C., ION, R.M., J. Nanosci. Nanotechnol., 12, 2012, , p. 1.
- 19. LACATUSU, I., BADEA, N., STAN, R., MEGHEA, A., Nanotechnology, **23**, 2012, p. 455702.
- 20. GOPALA, R.T.V., SUDIP, K.S., AMRUTA, S., SOUMYA, S., Int. J. Chem. Res., 2010, **2**, p. 8.
- 21. NASTI, T.H., KHAN, M.A., OWAIS, M., J. Antimicrob. Chemoth., 2006, **57**, p. 349.
- 22. KHALIL, R., KASSEM, M., ELBARY A.A., EL RIDI M., SAMRA M.A., KHALIL et al., IJPSR, 4, 2013, p. 2292.
- 23. BUNGHEZ, I.R., BARBINTA PATRASCU, M.E., BADEA, N., DONCEA, S.M., POPESCU, A., ION, R.M., Journal of Optoelectronics and Advanced Materials, **14**, **2012**, p. 1016.

Manuscript received: 10.02.2014